全球血液学恶性肿瘤治疗市场根据Polaris市场研究发布的一项新的研究，预计大小将达到2025亿美元以上的870亿美元。yabo官网入口
Hematological malignancy is a type of cancer that affect the bone marrow, blood, and lymph nodes. They include several forms of myeloma, leukemia, and lymphoma. According to an industry report in 2011, Hematological malignancies constituted 9% of all newly diagnosed malignancies in the U.S. specifying that lymphomas are more prevalent than myeloma or leukemias. Excluding Hodgkin’s lymphoma as well as acute lymphocytic leukemia, these types of malignancy are usually related to growing age. Hence, considering the aging worldwide population, malignancy type is more probable to become more prevalent.
全球血液学恶性肿瘤治疗性市场增长是由于新型治疗的发展和生长发生的血癌的发展，主要是推动。目前，血恶性肿瘤是癌症死亡的第二次主要原因和5th最常见的癌症。三种最常见的血液癌是多种骨髓瘤白血病和淋巴瘤。每年，约有40万人被诊断为淋巴瘤，超过30,000人被诊断出全球白血病。此外，预计血癌新药的发明及其监管批准的发明将加强市场增长。例如，2015年，PFizer宣布其抗体 - 药物缀合物 - Inotuzumab已获得急性淋巴细胞白血病的USFDA批准。
全球血液学恶性肿瘤治疗市场is segmented on the basis of type, therapy, and geography. Based on type, the market is segmented into leukemia, lymphoma, multiple myeloma, and others. The leukemia is further segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. On the basis of type, leukemia was estimated to dominate the market. The major market share is due to availability of products such as Imbruvica, Rituxan, and Glivec, which are estimated to be the highest revenue generating drugs. On the basis of therapy, the global Hematologic Malignancies Therapeutics Market is segmented into Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others. Amongst all the therapies, chemotherapy is the most commonly used treatment with a particular drug or combination of drugs used.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:
//m.nkkjrh.com/Industry-analysiss/hematologic-malignancies-therapeutics-market.
在地区的基础上，全球血液学恶性肿瘤治疗市场被分段为北美，欧洲，亚太地区，拉丁美洲和中东和非洲。北美估计占据全球市场。主导地位主要归因于关键市场参与者的高度，品牌药物的可用性，既定的医疗组织，以及增加该地区的政府支持。yabo娱乐vip然而，亚太地区预计将在预测期间主导全球市场。提高对早期诊断的认识，新兴国家的有效待遇的可用性，如印度和中国，不断增长的医疗保健支出以及患者的高度未满足的临床需求，是预计的一些因素，在亚太地区大大提振市场。yabo娱乐vip
Some major key players in global Hematologic Malignancies Therapeutics Market includes Pfizer, Inc., F. Hoffmann-LA Roche ltd, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, Inc., Novartis AG, GlaxoSmithKline PLC, Celgene Corporation, Johnson & Johnson Services, Inc., and Takeda Pharmaceutical Company limited among others. The object of the key market players is to deliver better chronic care administration while keeping the cost low. In addition, the companies are concentrating on producing easy-to-use monitoring devices that can aid patients to accomplish conditions including diabetes or heart diseases better by avoiding costly medical processes.